MRUS
Merus N.V.
Company Overview
| Mkt Cap | $7.27B | Price | $95.76 |
| Volume | 1.69M | Change | -0.23% |
| P/E Ratio | -33.7 | Open | $95.90 |
| Revenue | $36.1M | Prev Close | $95.98 |
| Net Income | $-215.3M | 52W Range | $33.19 - $96.28 |
| Div Yield | N/A | Target | $95.77 |
| Overall | 70 | Value | 40 |
| Quality | -- | Technical | 100 |
No chart data available
About Merus N.V.
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Latest News
Merus N.V. Shareholders to Vote on Genmab Acquisition Offer
Barclays Sticks to Its Hold Rating for Merus (MRUS)
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Merus (MRUS)
Merus NV’s Financial Stability at Risk Due to Unproven ADClonics Technology and Supply Chain Vulnerabilities
Merus NV Faces Uncertainty and Risks Amid Genmab A/S Transaction Delays
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MRUS | $95.76 | -0.2% | 1.69M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |